Loading company…
Yantai medical company developing drugs for cancer, autoimmune and eye diseases, including Telitacicept and Disitamab Vedotin.
Founded in 2008 and based in Yantai, China, Remegen, Ltd. researches and develops drugs for cancer, ophthalmic and autoimmune diseases. Its products include Telitacicept and Disitamab Vedotin, and its RC28 fusion protein has entered Phase 3 clinical study for ophthalmic treatments. Founder and CEO Jianmin Fang graduated from Harvard University. The company raised approximately USD 100 million in strategic investment in March 2020 and was listed on the Hong Kong Stock Exchange in November 2020.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in